M&A Deal Summary |
|
|---|---|
| Date | 2015-01-09 |
| Target | Aptuit - Aseptic Clinical Manufacturing |
| Sector | Life Science |
| Buyer(s) | Curia |
| Sellers(s) | Aptuit |
| Deal Type | Divestiture |
| Deal Value | 60M USD |
SEARCH BY
Try For Free 7-Day Free Trial
| Category | Company |
|---|---|
| Founded | 1991 |
| Sector | Life Science |
| Employees | 2,220 |
| Revenue | 402M USD (2015) |
Curia is a provider of global contract research and manufacturing services to the pharmaceutical and biotechnology industries. The company's services include drug discovery, such as medicinal chemistry, discovery biology, and in vitro ADME, development, such as pre-formulation, formulation and validation and manufacturing, such as CGMP API manufacturing. Curia was founded in 1991 and is based in Albany, New York.
| DEAL STATS | # |
|---|---|
| Overall | 5 of 11 |
| Sector (Life Science) | 3 of 9 |
| Type (Divestiture) | 1 of 3 |
| Country (United Kingdom) | 2 of 2 |
| Year (2015) | 1 of 3 |
| Size (of disclosed) | 4 of 7 |
| DATE | TARGET | DEAL TYPE | VALUE |
|---|---|---|---|
| 2014-06-02 |
OSO BioPharmaceuticals Manufacturing
Albuquerque, New Mexico, United States OsoBio is a leading contract manufacturer of injectable pharmaceutical products. The company provides glass vial filling and lyophilization services for drugs and biologics that are either approved for commercial marketing or in clinical development. With facilities equipped to handle highly potent and toxic active pharmaceutical ingredients, OsoBio focuses on the production of products that require special or complex handling. |
Buy | $110M |
| DATE | TARGET | DEAL TYPE | VALUE |
|---|---|---|---|
| 2015-07-16 |
Gadea Grupo Farmacéutico SL
Valladolid, Spain Gadea Grupo Farmacéutico SL (Gadea Pharmaceutical Group) is a technically complex active pharmaceutical ingredients (APIs) and finished drug product. |
Buy | $174M |
| Category | Company |
|---|---|
| Founded | 2004 |
| Sector | Life Science |
| Revenue | 88M USD (2016) |
Aptuit LLC is a provider of integrated early discovery to mid-phase drug development services in the pharmaceutical industry including Drug Design & Discovery, API Development and Manufacture, Solid State Chemistry, CMC, Preclinical and IND enabling GLP/GMP programs. Fully integrated drug discovery & development services are available from our facilities in the UK, Italy, and Switzerland.
| DEAL STATS | # |
|---|---|
| Overall | 1 of 1 |
| Sector (Life Science) | 1 of 1 |
| Type (Divestiture) | 1 of 1 |
| Country (United Kingdom) | 1 of 1 |
| Year (2015) | 1 of 1 |
| Size (of disclosed) | 1 of 1 |
| DATE | TARGET | DEAL TYPE | VALUE |
|---|---|---|---|
| 2010-06-30 |
GlaxoSmithKline - Medicines Research Centre
Verona, Italy GlaxoSmithKline - Medicines Research Center is a global network of operations that provides a full suite of development services. The agreement also enhances Aptuit’s ability to serve customers working to develop compounds for high-value and strategically important therapeutic areas such as neurosciences discovery and development, as well as cardiovascular and infectious diseases. |
Buy | - |
| DATE | TARGET | DEAL TYPE | VALUE |
|---|---|---|---|
| 2016-04-21 |
Exquiron Biotech AG
Reinach, Switzerland Exquiron Biotech AG is a specialist Contract Research Organization dedicated to early phase drug discovery solutions. Exquiron offers industry major expertise in assay development for hit finding and profiling purposes, high throughput screening, selectivity testing and hit characterization. These services are complemented by an extensive library collection of lead like compounds, as well as deep scientific knowledge in compound selection and Structure Activity Relationship (SAR) expansion across a broad range of targets in multiple therapeutic areas. |
Buy | - |
